Kohjin Bio Co., Ltd. (TYO:177A)

Japan flag Japan · Delayed Price · Currency is JPY
1,202.00
-18.00 (-1.48%)
At close: Feb 6, 2026
-20.56%
Market Cap6.14B -24.5%
Revenue (ttm)5.20B +9.1%
Net Income719.00M +87.2%
EPS140.67 +52.6%
Shares Out5.11M
PE Ratio8.55
Forward PEn/a
Dividend25.00 (2.05%)
Ex-Dividend Daten/a
Volume5,000
Average Volume7,310
Open1,241.00
Previous Close1,220.00
Day's Range1,202.00 - 1,244.00
52-Week Range1,191.00 - 2,020.00
Betan/a
RSI17.26
Earnings DateFeb 13, 2026

About Kohjin Bio

Kohjin Bio Co., Ltd. manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures. It also provides industrial cell cultures for CHO, hybridomas, and insect cells; exosome production; cryopreserva... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1981
Employees 167
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 177A
Full Company Profile

Financial Performance

In fiscal year 2025, Kohjin Bio's revenue was 5.21 billion, an increase of 9.14% compared to the previous year's 4.77 billion. Earnings were 794.00 million, an increase of 106.77%.

Financial Statements